These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 29492747

  • 1. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017.
    Scott FI, Lichtenstein GR.
    Curr Treat Options Gastroenterol; 2018 Mar; 16(1):147-164. PubMed ID: 29492747
    [Abstract] [Full Text] [Related]

  • 2.
    Padda IS, Bhatt R, Parmar M.
    ; 2024 01. PubMed ID: 34662086
    [Abstract] [Full Text] [Related]

  • 3. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.
    Chang S, Hanauer S.
    Curr Treat Options Gastroenterol; 2017 Mar; 15(1):53-70. PubMed ID: 28164249
    [Abstract] [Full Text] [Related]

  • 4. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N.
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [Abstract] [Full Text] [Related]

  • 5. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P, Fiorino G, Danese S.
    Curr Pharm Des; 2017 Nov; 23(44):6759-6769. PubMed ID: 29205114
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L, Peyrin-Biroulet L.
    Curr Med Chem; 2019 Nov; 26(2):270-279. PubMed ID: 27758715
    [Abstract] [Full Text] [Related]

  • 7. Biosimilars in ulcerative colitis: When and for who?
    Ilias A, Gonczi L, Kurti Z, Lakatos PL.
    Best Pract Res Clin Gastroenterol; 2018 Nov; 32-33():35-42. PubMed ID: 30060937
    [Abstract] [Full Text] [Related]

  • 8.
    ; 2017 01 18. PubMed ID: 28727394
    [Abstract] [Full Text] [Related]

  • 9. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.
    McConachie S, Wilhelm SM, Kale-Pradhan PB.
    Expert Rev Clin Pharmacol; 2017 Apr 18; 10(4):391-400. PubMed ID: 28095262
    [Abstract] [Full Text] [Related]

  • 10. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A, National patients’ association representatives.
    Dig Liver Dis; 2019 May 18; 51(5):632-639. PubMed ID: 30872085
    [Abstract] [Full Text] [Related]

  • 11. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
    Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL.
    Clin Gastroenterol Hepatol; 2016 Dec 18; 14(12):1685-1696. PubMed ID: 27215364
    [Abstract] [Full Text] [Related]

  • 12. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, Danese S.
    Expert Opin Biol Ther; 2019 Oct 18; 19(10):1023-1030. PubMed ID: 30601098
    [Abstract] [Full Text] [Related]

  • 13. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo M, Fiorino G, Gilardi D, Furfaro F, Roda G, Loy L, Allocca M, Peyrin-Biroulet L, Danese S.
    Curr Pharm Des; 2019 Oct 18; 25(1):7-12. PubMed ID: 30864505
    [Abstract] [Full Text] [Related]

  • 14. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M, Sciascia S, Roccatello D, Cuadrado MJ.
    BioDrugs; 2017 Feb 18; 31(1):37-49. PubMed ID: 28035633
    [Abstract] [Full Text] [Related]

  • 15. Biosimilars in Inflammatory Bowel Disease.
    Buchner AM, Schneider Y, Lichtenstein GR.
    Am J Gastroenterol; 2021 Jan 01; 116(1):45-56. PubMed ID: 33110013
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ, Curiale C, Petersel D, Rolland C, Jones H, Mysler E.
    BioDrugs; 2018 Jun 01; 32(3):193-199. PubMed ID: 29790131
    [Abstract] [Full Text] [Related]

  • 17. Biosimilar biological drugs in the treatment of inflammatory bowel diseases.
    Kaniewska M, Eder P, Gąsiorowska A, Gonciarz M, Kierkuś J, Małecka-Panas E, Rydzewska G.
    Prz Gastroenterol; 2019 Jun 01; 14(4):223-227. PubMed ID: 31988667
    [Abstract] [Full Text] [Related]

  • 18. Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico.
    Mayoral-Zavala A, Esquivel-Aguilar A, Del Real-Calzada CM, Gutiérrez-Grobe Y, Ramos-García J, Rocha-Ramírez JL, Rojas-Illanes MF, Rubio-Martínez B, Sánchez-Chávez X, Yamamoto-Furusho JK, Grupo Académico y de Investigación en Crohn y Colitis Ulcerosa Idiopática de México (GAICCUM).
    Rev Gastroenterol Mex (Engl Ed); 2018 Jun 01; 83(4):414-423. PubMed ID: 29685744
    [Abstract] [Full Text] [Related]

  • 19. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.
    Rawla P, Sunkara T, Raj JP.
    J Inflamm Res; 2018 Jun 01; 11():215-226. PubMed ID: 29844695
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.